JP2024526939A - 酸化的網膜疾患の進行を抑制する方法 - Google Patents

酸化的網膜疾患の進行を抑制する方法 Download PDF

Info

Publication number
JP2024526939A
JP2024526939A JP2024503840A JP2024503840A JP2024526939A JP 2024526939 A JP2024526939 A JP 2024526939A JP 2024503840 A JP2024503840 A JP 2024503840A JP 2024503840 A JP2024503840 A JP 2024503840A JP 2024526939 A JP2024526939 A JP 2024526939A
Authority
JP
Japan
Prior art keywords
day
progression
ester
patient
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503840A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023004151A5 (https=
JP2024526939A5 (https=
Inventor
シュミット カルステン
シチェピノフ ミハイル
Original Assignee
バイオジーバ リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオジーバ リミティド ライアビリティ カンパニー filed Critical バイオジーバ リミティド ライアビリティ カンパニー
Publication of JP2024526939A publication Critical patent/JP2024526939A/ja
Publication of JPWO2023004151A5 publication Critical patent/JPWO2023004151A5/ja
Publication of JP2024526939A5 publication Critical patent/JP2024526939A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024503840A 2021-07-22 2022-07-22 酸化的網膜疾患の進行を抑制する方法 Pending JP2024526939A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163224690P 2021-07-22 2021-07-22
US202163224679P 2021-07-22 2021-07-22
US202163224674P 2021-07-22 2021-07-22
US63/224,679 2021-07-22
US63/224,690 2021-07-22
US63/224,674 2021-07-22
PCT/US2022/038072 WO2023004151A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Publications (3)

Publication Number Publication Date
JP2024526939A true JP2024526939A (ja) 2024-07-19
JPWO2023004151A5 JPWO2023004151A5 (https=) 2024-07-29
JP2024526939A5 JP2024526939A5 (https=) 2024-07-29

Family

ID=84979648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503840A Pending JP2024526939A (ja) 2021-07-22 2022-07-22 酸化的網膜疾患の進行を抑制する方法

Country Status (8)

Country Link
US (1) US20250099415A1 (https=)
EP (1) EP4373479A4 (https=)
JP (1) JP2024526939A (https=)
KR (1) KR20240036651A (https=)
AU (1) AU2022313207A1 (https=)
CA (1) CA3227139A1 (https=)
IL (1) IL310210A (https=)
WO (1) WO2023004151A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024049497A1 (en) * 2022-09-02 2024-03-07 Biojiva Llc Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514328A (ja) * 2011-04-26 2014-06-19 レトロトップ、 インコーポレイテッド 酸化的網膜疾患
JP2019501135A (ja) * 2015-11-23 2019-01-17 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． １，４−ジエン系の部位特異的同位体標識

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
CA2723139A1 (en) * 2007-07-30 2009-02-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
WO2009058815A2 (en) * 2007-10-29 2009-05-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lipoxin a4 protection for retinal cells
CA3117216A1 (en) * 2018-11-15 2020-05-22 Retrotope, Inc. Deuterated compounds, compositions, and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514328A (ja) * 2011-04-26 2014-06-19 レトロトップ、 インコーポレイテッド 酸化的網膜疾患
JP2019501135A (ja) * 2015-11-23 2019-01-17 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． １，４−ジエン系の部位特異的同位体標識

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENNIS R. HOFFMAN, ET AL.: ""Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Out", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 56, no. 11, JPN6025039316, 2015, pages 6646 - 6653, ISSN: 0005698257 *
MELISSA ROSELL, ET AL.: "Bis-allylic Deuterated DHA Alleviates Oxidative Stress in Retinal Epithelial Cells"", ANTIOXIDANTS, vol. 8, no. 10, JPN6025039315, 2019, pages 447, ISSN: 0005698256 *

Also Published As

Publication number Publication date
EP4373479A4 (en) 2025-11-05
EP4373479A1 (en) 2024-05-29
KR20240036651A (ko) 2024-03-20
US20250099415A1 (en) 2025-03-27
IL310210A (en) 2024-03-01
AU2022313207A1 (en) 2024-02-29
CA3227139A1 (en) 2023-01-26
WO2023004151A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP7227003B2 (ja) ウロリチン化合物を含む組成物
JPH02243623A (ja) 脂肪酸による治療および組成物
JPH0369886B2 (https=)
JPH11209279A (ja) 体重減少および肥満処置の方法
JP2002518440A (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
EP0342956A2 (en) Use of phytic acid or its salts for the treatment of hyperlipemia, obesity and obesity-related diseases
WO2009057994A1 (en) Unit dosage for brain health
WO2003072111A2 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
JP2022537366A (ja) Ｌｐｃ－ｄｈａ、ｌｐｃ－ｅｐａなどの非経口リゾホスファチジルコリン製剤及びそれらの治療における使用
JP2024526939A (ja) 酸化的網膜疾患の進行を抑制する方法
US20230255917A1 (en) Methods of treating amyotrophic lateral sclerosis
US7033612B2 (en) Composition and method for treating age-related disorders
CN118019529A (zh) 抑制氧化性视网膜疾病进展的方法
US20240091187A1 (en) Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof
JP2004115429A (ja) 視力向上剤
US20200085774A1 (en) Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia
JP3816545B2 (ja) 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
JP2025507361A (ja) 網膜酸化的疾患の治療に対する患者の反応をモニタリングする方法
JP2004067537A (ja) 交感神経の興奮抑制剤
JPH0319208B2 (https=)
JP2025506208A (ja) Ａｌｓ治療のための相乗的併用療法
KR20260010331A (ko) L-세린의 리포좀 제형 및 이의 제조 방법
WO2025149953A1 (en) Ozonised oil for use in the prevention and/or treatment of age-related macular degeneration
JPS6221333B2 (https=)
JPH05139966A (ja) 月経困難症予防または治療剤と月経困難症予防機能性食品

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260330